¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"insulin convulsive therapy combined"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • compression therapy
    ¾Ð¹Ú¿ä¹ý
  • conjoint therapy
    ÇÕµ¿¿ä¹ý
  • consolidation therapy
    °­È­¿ä¹ý
  • corrective therapy
    ±³Á¤¿ä¹ý
  • couples therapy
    ºÎºÎ¿ä¹ý
  • drug therapy
    ¾à¹°¿ä¹ý
  • diathermic therapy
    Åõ°ú¿­¿ä¹ý
  • directive group therapy
    Áö½ÃÁý´Ü¿ä¹ý
  • electric shock therapy
    Àü±âÃæ°Ý¿ä¹ý
  • electroconvulsive therapy
    Àü±â°æ·Ã¿ä¹ý
  • endocrine therapy
    ³»ºÐºñ¿ä¹ý
  • estrogen replacement therapy
    ¿¡½ºÆ®·Î°Õ´ëÄ¡¿ä¹ý
  • fever therapy
    ¹ß¿­¿ä¹ý
  • gene therapy
    À¯ÀüÀÚ¿ä¹ý
  • gene transfer therapy
    À¯ÀüÀÚÀ̽Ŀä¹ý
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • conformal dynamic therapy
    ÀÔüÁ¶Çüµ¿Àû¿ä¹ý
  • conformal radiation therapy
    ÀÔüÁ¶Çü¹æ»ç¼±¿ä¹ý
  • conjoint therapy
    ÇÕµ¿¿ä¹ý
  • consolidation therapy
    °­È­¿ä¹ý
  • corrective therapy
    ±³Á¤¿ä¹ý
  • couples therapy
    ºÎºÎ¿ä¹ý
  • curative radiation therapy
    Ä¡À¯¹æ»ç¼±Ä¡·á, ±ÙÄ¡¹æ»ç¼±¿ä¹ý
  • diathermic therapy
    Åõ¿­¿ä¹ý
  • didactic group therapy
    ±³À°Áý´Ü¿ä¹ý
  • directive group therapy
    Áö½ÃÁý´Ü¿ä¹ý
  • drug therapy
    ¾à¹°¿ä¹ý
  • electoconvulsive therapy
    Àü±â°æ·Ã¿ä¹ý
  • electric shock therapy
    Àü±âÃæ°Ý¿ä¹ý
  • embolic therapy
    »öÀüÄ¡·á, ¸·±âÄ¡·á
  • endocrine therapy
    ³»ºÐºñ¿ä¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • immunosuppressive therapy
    ¸é¿ª¾ïÁ¦¿ä¹ý
  • implosive therapy
    ³»ÆÄ Ä¡·á
  • inhalation therapy =i. treatment
    ÈíÀÔ ¿ä¹ý.
  • intensification therapy
    Áõ°­¿ä¹ý.
  • intensity modulated radiation therapy
    °­µµº¯Á¶ ¹æ»ç¼±Ä¡·á
  • photodynamic therapy
    ±¤¼±¿ªÇпä¹ý
  • photodynamic therapy
    ±¤¿ªÇÐÄ¡·á
  • physical therapy
    ¹°¸®Ä¡·á,¹°¸®¿ä¹ý
  • physical therapy technician
    ¹°¸® ¿ä¹ý ±â»ç(ÚªìµèþÛöÐüÞÔ).
  • play therapy
    ³îÀÌ¿ä¹ý,³îÀÌÄ¡·á,À¯Èñ¿ä¹ý.
  • postmenopausal hormone therapy
    Æó°æ±â È£¸£¸ó Ä¡·á
  • postoperative radiation therapy
    (¼ö)¼úÈĹæ»ç¼±Ä¡·á
  • preoperative radiation therapy
    (¼ö)¼úÀü ¹æ»ç¼±Ä¡·á
  • prolonged sleep therapy
    Áö¼Ó¼ö¸é¿ä¹ý, Àå±â¼ö¸é¿ä¹ý(íåÑ¢â²ØùèþÛö).
  • protein therapy
    ´Ü¹é(Áú)¿ä¹ý(¡­èþÛö).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • severe combined immunodeficiency
    ÁßÁõº¹Çո鿪°áÇÌÁõ
  • severe combined immunodeficiency disease
    ÁßÁõº¹Çո鿪°áÇ̺´(ñìñøÜÜùêØóæ¹ÌÀù¹Ü»)
  • subacute combined degeneration
    ¾Æ±Þ¼º ¿¬ÇÕ¼º º¯¼º(¡­æáùêàõܨàõ).
  • subacute combined degeneration
    ¾Æ±Þ¼º ¿¬ÇÕ¼º º¯¼º(¡­æáùêàõܨàõ)
  • anti-insulin
    Ç×Àν¶¸°.
  • arginine-insulin test
    ¾Æ¸£±â´Ñ-Àν¶¸°½ÃÇè
  • beta cell insulin cell
    º£Å¸¼¼Æ÷ Àν´¸°¼¼Æ÷
  • crystalline insulin
    °áÁ¤¼º Àν¶¸°.
  • crystalline zinc insulin
    °áÁ¤¼º ¾Æ¿¬(Ì¿ïÜàõ䬿ç)Àν¶¸°.
  • depot insulin
    ÀúÀåÀν¶¸°.
  • diabetes mellitus,insulin deficiency
    Àν¶¸° °áÇÌÁõ(¡­ÌÀù¹ñø)
  • diabetes mellitus,insulin resistance
    Àν¶¸° ÀúÇ×(¼º)(¡­î½ù÷àõ)
  • diabetes mellitus,insulin-dependent
    Àν¶¸° ÀÇÁ¸¼º(¡­ëîðíàõ)
  • diabetes mellitus,non-insulin-dependent
    ºñ-Àν¶¸° ÀÇÁ¸¼º(Þª¡­)
  • globin insulin
    ±Û·ÎºóÀν¶¸°.
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
IRS immunoreactive secretion; infrared spectrophotometry; insulin receptor species; insulin receptor sub...
AART American Association for Rehabilitation Therapy; American Association for Respiratory Therapy
ACT achievement through counseling and treatment; actin; actinomycin; activated clotting time; advanced ...
ERT esophageal radionuclide transit; estrogen replacement therapy; examination room terminal; external r...
OT objective test; oblique talus; occlusion time; occupational therapist, occupational therapy; ocular ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
SCID Severe Combined ImmunoDeficient
SCID Severe Combined Immunodeficiency Disease
X-SCID X-linked severe combined immunodeficiency
scid mice severe combined immune deficiency
ADT Androgen deprivation therapy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • exercise therapy
    ¿îµ¿ Ä¡·á
  • extension therapy
    °ßÀÎ ¿ä¹ý
    Áö¼ÓÀûÀ¸·Î °ßÀηÂÀ» ÀÛ¿ë½ÃÄÑ ±ÙÀ°À» Ä¡·áÇÏ´Â ¹ý. ±ÙÀ°Àº Ÿ¹ÚÀ̳ª ¿Ü»ó ¶§ ÀåÃà ¹æÇâÀ¸·Î ´ÜÃàµÇ´Â ÀÏÀÌ ¸¹¾Æ¼­, ¿°ÁÂ, Á»ó, ±×¸®°í ¾î¶² Á¾·ùÀÇ °ñÀý¿¡¼­´Â ÀåÃà ¹æÇâÀ¸·Î Áö¼ÓÀûÀ¸·Î °ßÀÎÇÒ Çʿ䰡 ÀÖ´Ù. °£´ÜÇÑ °ßÀοä¹ýÀ¸·Î´Â ¹Ýâ°íÀÇ ÀÀ¿ëÀÌ ÀÖÀ¸¸ç, ±³Åë»ç°í ¶§ ¸¹ÀÌ ÀϾ´Â °æÃß ¿°Á¿¡´Â ¾Æ·¡ÅÎÀ» °íÁ¤½Ã۰í üÁßÀ» ÀÌ¿ëÇÏ´Â °ßÀαⰡ °í¾ÈµÇ¾î ÀÖ´Ù. ±× ¹Û¿¡ °­¼±À» Ȱ¿ëÇÏ¿© »À¿¡ Á÷Á¢ °ßÀηÂÀ» ¹ÌÄ¡´Â ¹æ¹ýµµ ÀÖ´Ù.
  • fluid therapy
    ¼ö¾× ¿ä¹ý
  • fluoride therapy
    ºÒ¼Ò Ä¡·á, ºÒ¼Ò óġ
  • heat and cold therapy
    ³Ã¿Â ¿ä¹ý
    Â÷°¡¿î ÆÐµå¿Í ¶ß°Å¿î ÆÐµå¸¦ ¹ø°¥¾Æ°¡¸ç º´¼Ò¿¡ ´ë°í Ç÷¾× ¼øÈ¯À» ÃËÁø½Ã۰í ÅëÁõÀ» ¿ÏÈ­½ÃŰ´Â ¹æ¹ý.
  • indirect pulp therapy
    °£Á¢ Ä¡¼ö Ä¡·á
  • infrared laser therapy
    Àû¿Ü¼± ·¹ÀÌÀú ¿ä¹ý
    µ¿ÀǾî=cold laser thera
  • initial therapy
    Ãʱâ Ä¡·á
  • irreversible occlusal therapy
    ºñ°¡¿ªÀûÀÎ ±³ÇÕ Ä¡·á, ºñ°¡¿ªÀû ±³ÇÕ Ä¡·á
  • laser therapy
    ·¹ÀÌÀú Ä¡·á
    ÁÖ·Î ÃâÇ÷ÀÌ Àû¾î¾ß Çϰųª µ¿ÅëÀÌ ½ÉÇÑ È¯ÀÚÀÇ ¼ö¼úÀ̳ª »óóÀÇ À¶ÇÕ, Á¶Á÷ÀÇ ÆÄ±« µî¿¡ »ç¿ëµÈ´Ù.
  • light therapy
    ±¤¼± Ä¡·á
  • microwave therapy
    ±ØÃÊ´ÜÆÄ ¿ä¹ý
    ÆÄÀå 1 m ÀÌÇÏ, 1 mm ÀÌ»óÀÇ ÀüÀÚÆÄ¸¦ ÀÌ¿ëÇÏ´Â Àü±â¿ä¹ý. ¸¶ÀÌÅ©·Î¿þÀÌºê ¿ä¹ý , ¸¶ÀÌÅ©·ÎÆÄ ¿ä¹ýÀ̶ó°íµµ ÇÑ´Ù. º¸Åë ÀÇ·á¿ë¿¡´Â 12.5 cmÀÇ ÆÄÀåÀÌ Ã¤¿ëµÇ°í ÀÖ´Ù. ¸¶±×³×Æ®·ÐÀ̶ó´Â Áø°ø°ü¿¡¼­ ¹ßÁøµÇ¾î ¹Ý¿øÇü ¶Ç´Â °¢ÇüÀÇ Á¶»ç ÀåÄ¡·Î 5~10 cmÀÇ °Å¸®¿¡¼­ ȯºÎ¸¦ Á¶»çÇÑ´Ù. ÀÎü¿¡ Á¶»çÇÏ¿´À» ¶§ 3~4 cm¿¡¼­ ´ëºÎºÐ Èí¼öµÇ°í, ±× ¿¡³ÊÁö´Â ¿­·Î º¯ÇÑ´Ù. Áï, ½É´Þ¼ºÀº ÃÊ´ÜÆÄº¸´Ù ÀÛ°í Àû¿Ü¼±º¸´Ù´Â Å©´Ù. ±×·¸°Ô ±íÁö ¾ÊÀº Á¶Á÷¿¡ ´ëÇÑ ¿Â¿­¿ä¹ýÀ¸·Î ¾²À̸ç, ³ú, ´«, °íȯ µî°ú °°ÀÌ Ç÷ÇàÀÌ ÀûÀº ±â°ü¿¡¼­´Â °ú¿­µÉ À§ÇèÀÌ ÀÖÀ¸¹Ç·Î Á¶»çÇÒ ¶§ ÁÖÀǰ¡ ÇÊ¿äÇÏ´Ù.
  • music therapy
    À½¾Ç ¿ä¹ý
  • non-reversible therapy
    ºñ°¡¿ªÀûÀÎ Ä¡·á
  • nonvital pulp therapy technique
    ½ÇȰ Ä¡¼ö Ä¡·á ¼ú½Ä
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
insulin-dependent diabetes mellitus A chronic condition in which the pancreas makes little or no insulin because the beta cells have been destroyed. The body is then not able to use the glucose (blood sugar) for energy. IDDM usually comes on abruptly, although the damage to the beta cells may begin much earlier. The signs of IDDM are a great thirst, hunger, a need to urinate often, and loss of weight. To treat the disease, the person must inject insulin, follow a diet plan, exercise daily, and test blood glucose several times a day. IDDM usually occurs in children and adults who are under age 30. This type of diabetes used to be known as juvenile diabetes, juvenile-onset diabetes, and ketosis-prone diabetes.
(09 Oct 1997)
insulin hypoglycaemia test A test to determine the completeness of vagotomy for peptic ulcer; after the surgical procedure is performed, insulin is administered to cause hypoglycaemia; if vagotomy is complete, the acid output from the stomach following administration of insulin is less than that before insulin administration; if the reverse if true, incomplete vagotomy is likely.
Synonym: Hollander test.
(05 Mar 2000)
insulin infusion systems Portable or implantable devices for infusion of insulin. Includes open-loop systems which may be patient-operated or controlled by a pre-set program and are designed for constant delivery of small quantities of insulin, increased during food ingestion, and closed-loop systems which deliver quantities of insulin automatically based on an electronic glucose sensor.
(12 Dec 1998)
insulin injection A preparation that may contain 20, 40, 80, 100, or 500 USP insulin units per ml, although the trend is toward standardizing all insulin preparations at 100 units per ml; it is administered subcutaneously, occasionally intravenously, and has a rapid onset of action, has a brief duration (5 to 7 hours), and is compatible for mixing with long-acting insulin preparations; used in the treatment of diabetic acidosis and insulin coma.
Synonym: regular insulin injection.
(05 Mar 2000)
insulin, isophane <chemical> An intermediate-acting insulin with an approximate time of onset of 2 hours and duration of action of 24 hours, consisting of bovine or pork insulin reacted with zinc chloride and protamine to form a protein complex with a ratio of free and bound insulin, providing action intermediate between regular insulin and protamine zinc insulin.
Pharmacological action: hypoglycaemic agents.
Chemical name: Insulin Isophane
(12 Dec 1998)
insulin, lente <chemical> Sterile suspension, in a buffered water medium, of insulin modified by the addition of zinc chloride in a manner such that the solid phase of the suspension conisists of a mixture of crystals and amorphous material in a ratio of approximately 7:3.
Pharmacological action: hypoglycaemic agents.
Chemical name: Insulin zinc
(12 Dec 1998)
insulin-like activity A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin.
(05 Mar 2000)
insulin like growth factor <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin.
They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present).
Insulin like growth factor I = somatomedin A = somatomedin C
Insulin like growth factor II = MSA (Multiplication stimulating activity).
Insulin like growth factor 1 is released from the liver in response to growth hormone.
Acronym: IGF
(18 Nov 1997)
insulin-like growth-factor binding protein 1 One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29)
(12 Dec 1998)
insulin-like growth factor-binding protein 2 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth factor binding protein 3 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin like growth-factor-binding protein 4 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth-factor-binding-protein 5 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like-growth-factor-binding protein 6 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth-factor-binding proteins A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (int j gynaecol obstet 1992;39(1):3-9)
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á